Subscribe to RSS
DOI: 10.1055/s-0036-1593015
Y-box protein-1/p18 as novel serum marker for ovarian cancer diagnosis: A study by the Tumor Bank Ovarian Cancer (TOC)
Introduction: The cold shock Y-box binding protein-1 (YB-1) fulfills important roles in regulating cell proliferation and differentiation. Overexpression occurs in various tumor cells. Given the existence of extracellular YB-1 we set out to determine the diagnostic, predictive and prognostic role of serum YB-1/p18 for patients with primary epithelial ovarian cancer (EOC).
Methods: YB-1/p18 was quantified by sandwich ELISA in serum samples from 132 healthy female volunteers and 206 patients with histological diagnosis of primary EOC.
Results: Median age at the time of diagnosis was 60 years and follow-up ended with a mean of 44.8 month. 188 (91%) patients were diagnosed at advanced stages (FIGO III/IV) and 188 patients (91%) suffered from high-grade serous ovarian carcinoma. YB-1/p18 levels were significantly decreased in older patients (p = 0.021). Significantly lower serum levels of YB-1/p18 were detected in the EOC cohort when compared to the control group (p < 0.0001, AUC = 0.827; 95% CI, 0.787 – 0.867). Using the expression of serum YB-1/p18 in early stages I and II cases these could be differentiated from control cases (p < 0.0001, AUC = 0.816; 95% CI 0.704 – 0.929). No other significant associations between clinical prognostic factors and YB-1/p18 serum levels were detected. Immunoblotting results with serum samples suggest that masking of epitopes by the YB-1/p18 fragment in multiprotein-complexes under non reducing conditions leads to the observed reduced ELISA readings in the EOC cohort.
Conclusions: The quantification of fragment YB-1/p18 derived from cold shock protein YB-1 in serum samples could be useful for the early diagnosis of EOC.